NCT02652793View on ClinicalTrials.gov

Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

Boosted atazanavir

Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly

DRUG

Lamivudine

Lamivudine 300 mg once dailly

Trial Locations (1)

08036

Hospital Clínic i Provincial de Barcelona, Barcelona

All Listed Sponsors
collaborator

Fundacion Clinic per a la Recerca Biomédica

OTHER

lead

Judit Pich

OTHER

NCT02652793 - Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia | Biotech Hunter | Biotech Hunter